Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA To the Editor: Rini et al. reported that thrombotic microangiopathy (TMA), a potentially life-threatening toxicity resulting from vascular endothelial growth factor (VEGF) inhibition, may be more likely in uninephrectomized renal cell carcinoma (RCC) patients, while no patient with a non-RCC malignancy in their cohort experienced TMA [1] . Literature review as well as our personal data casts doubt on the importance of a solitary kidney in TMA resulting from VEGF inhibition [2] [3] [4] [5] [6] [7] [8] [9] [10] (Table 1) . In 18 TMA reported cases in literature, only 6 cases of RCC patients who had experienced nephrectomy, chronic kidney disease, diabetes and hypertension have been mentioned [3, [8] [9] [10] . In our personal experience (unpublished data), only 5 out of 20 TMA cases had metastatic RCC (mRCC), underwent nephrectomy and had hypertension. The other 12 literature cases [2, [4] [5] [6] [7] (66.6%) as well as our own 15 remaining TMA cases (75%) had both kidneys, and <26% of them were diabetic and/or hypertensive and/or renal insufficient (Table 1) . TMA related to anti-VEGF-VEGFR agents (anti-VEGF agent such as bevacizumab or VEGF Trap, or VEGFR inhibitors such as sunitinib, sorafenib or pazopanib) is clearly a class effect, and the underlying renal and oncological conditions can, at best, be considered an undiscriminating predisposing factor. Moreover, the pathophysiology of TMA induced by the combination bevacizumab and sunitinib is clearly in relation to VEGF pathway inhibition.
Fifty percent of our patients did not show haematologic signs of TMA. Despite the fact that TMA related to anti-VEGF therapy might be selectively of renal expression, only half of the biopsied patients had grade 3 or 4 proteinuria. Therefore, TMA is under-diagnosed, and clinicians should be more attentive to mild renal anomalies in those patients. Patients showing proteinuria need special referral to nephrologists. Close follow-up of hypertension and/or proteinuria in all patients by the oncologists cannot be overemphasized. 
Haemorrhagic shock induced by subcutaneous insulin injection
Sir-A number of chronic kidney disease patients with diabetes receive intensive insulin therapy nowadays, and many of them are also treated for several comorbidities. The combination of insulin therapy and other comorbidities could result in an unexpected complication.
Case
A 61-year-old female with type 2 diabetes and rheumatoid arthritis was admitted to our hospital on February 2009 for the curettage of a knee prosthesis infection. Intensive insulin therapy with 32-gauge tip × 6 mm needles was initiated 3 years previously. She was administered warfarin 1.5 mg for atrial fibrillation, and prothrombin time-international normalized ratio was prolonged to 2.0. Other laboratory tests revealed decreased kidney function (serum creatinine, 124 μmol/L; estimated glomerular filtration rate, 26.3 mL/ min/1.73 m 2 ) and normal platelet count (220 × 10 9 /L).
One day during her hospital stay, she injected her regular insulin by herself under the surveillance of a nurse in the left lower quadrant of the abdominal wall. Thirty minutes later, a subcutaneous haematoma appeared around the injection site. The haematoma enlarged rapidly despite the strenuous manual pressure performed immediately, and she subsequently developed haemorrhagic shock. Computer tomography detected a massive subcutaneous haematoma (Figure 1 ). Massive transfusion of 12 units of red blood cells and 12 units of fresh frozen plasma, along with further compression of the abdominal wall, was performed, and her haemodynamics stabilized. Follow-up abdominal angiography, however, did not detect the bleeding artery.
Discussion
Subcutaneous haematoma caused by insulin injection is a very rare complication [1] [2] [3] . One report described that inappropriate maneuver of insulin injection triggered haemorrhagic shock [2] . Although our case had several risk factors, such as chronic kidney disease, diabetes, rheumatoid arthritis, post-operative state and usage of warfarin, insulin injection was used properly. The fact that haemorrhagic shock occurred in this case is a warning of possible complications of insulin injection in high-risk patients.
Although fine needles are remarkably thin, therefore considerably reducing the risk of haemorrhage [4] , lethal subcutaneous haematoma could happen even in a careful clinical setting.
